Curis announces $8.5 million stock and warrant offering at $0.51 per share
On October 16, 2026, Curis agreed to sell 16,666,680 shares, or pre-funded warrants in place of shares, with accompanying common warrants for up to 16,666,680 shares, at a combined price of $0.51 per share. Gross proceeds are expected to be about $8.5 million before placement agent fees and expenses, with closing expected on or about October 19, 2026. The company also agreed to lower the exercise price of its January and August 2026 warrants to $0.60, and the new share count and warrants would add to the shares outstanding for existing holders.
Key points
- Offering of 16,666,680 shares or pre-funded warrants, plus common warrants for up to 16,666,680 shares, at a combined $0.51 per share
- Gross proceeds expected to be about $8.5 million, before placement agent fees and offering expenses; placement agents to receive a 6.5% cash fee
- New common warrants have a $0.60 exercise price, become exercisable six months after issuance, and terminate April 19, 2032
- January 2026 and August 2026 warrants to be amended to a reduced exercise price of $0.60; proceeds expected to fund operations through initial CLL data in 5-10 patients in December 2026
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.